Stock BIT BIOTRON LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Biotron Limited

Equities

BIT

AU000000BIT4

Biotechnology & Medical Research

Delayed Australian S.E.
Other stock markets
 11:08:26 20/05/2024 am IST 		5-day change 1st Jan Change
0.055 AUD 0.00% Intraday chart for Biotron Limited -5.17% -43.30%
05/04 Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25% MT
26/02 Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Business Summary

Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.

Managers

Managers TitleAgeSince
Michelle Miller CEO
 Chief Executive Officer - 21/02/21
Stephen Becker CTO
 Chief Tech/Sci/R&D Officer - 17/20/17
Peter Nightingale SEC
 Corporate Secretary 67 23/99/23

Members of the board

Members of the board TitleAgeSince
Robert Thomas BRD
 Director/Board Member 79 07/12/07
Michael Hoy CHM
 Chairman 75 07/00/07
Michelle Miller CEO
 Chief Executive Officer - 21/02/21
Susan Pond BRD
 Director/Board Member - 07/12/07
Stephen Locarnini BRD
 Director/Board Member - 23/18/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 901,944,902 724,063,389 ( 80.28 %) 0 80.28 %

Shareholders

NameEquities%Valuation
Jey Investment Pty Ltd.
2.687 %
24,240,000 2.687 % 897 122 $
Rookharp Capital Pty Ltd.
1.692 %
15,267,176 1.692 % 565 038 $
Umbiram Pty Ltd.
1.243 %
11,217,352 1.243 % 415 154 $
Michael Hoy
1.243 %
11,217,352 1.243 % 415 154 $
Angela Fay Dr Dulhunty
1.108 %
10,000,000 1.108 % 370 100 $
Fordholm Investments Pty Ltd.
1.031 %
9,300,000 1.031 % 344 193 $
Travis Fountain
0.9862 %
8,897,892 0.9862 % 329 311 $
Attollo Copia Pty Ltd.
0.8612 %
7,770,678 0.8612 % 287 593 $
Sked Pty Ltd.
0.8270 %
7,462,000 0.8270 % 276 169 $
William John Dunn
0.8091 %
7,300,000 0.8091 % 270 173 $

Company contact information

Biotron Ltd.

56 Delhi Road Suite 3.3

2113, North Ryde

+

http://www.biotron.com.au
address Biotron Limited(BIT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOTRON LIMITED Stock Biotron Limited
-43.30% 3.32Cr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 11TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 11TCr
ARGENX SE Stock argenx SE
-2.59% 2.2TCr
BIONTECH SE Stock BioNTech SE
-12.38% 2.19TCr
GENMAB A/S Stock Genmab A/S
-5.29% 1.92TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 1.81TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 1.77TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 1.43TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 1.24TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIT Stock
  4. Company Biotron Limited
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW